HAYWARD, Calif., June 5, 2013 /PRNewswire/ -- Rafael Simon, a veteran in the environment and energy industries, has joined Microvi Biotechnologies as Chairman of its Board of Directors. Rafael was the COO of Zenon Environmental, a leading water treatment company, previous to its acquisition by GE Water in 2006 for nearly $700 M.
(Photo: http://photos.prnewswire.com/prnh/20130605/PH26398 )
While at Zenon, Rafael was responsible for all aspects of sales, operations, R&D and manufacturing. During his tenure at Zenon, share price tripled and he was named Canada's top COO by Canadian Business, Canada's leading business magazine.
"Rafael brings expertise in strategy and a depth of knowledge in our market focus that will be important in Microvi's continuing commercialization of its MicroNiche Engineering Platform Technology," said Dr. Fatemeh Shirazi, CEO of Microvi. "I am delighted to welcome him as Chairman of Microvi's Board of Directors."
He joins Microvi at a pivotal growth period, building on successful scaling and commercialization of the company's platform technology and various biocatalytic solutions for clean water, renewable biofuels, biochemicals and other industrial bioprocesses.
"I'm excited to have the opportunity to help scale-up the revolutionary Microvi biocatalyst technology which has the potential to disrupt so many industries," said Rafael.
Previous to his work with Zenon, Rafael worked at McKinsey & Company specializing in corporate growth strategies for water and energy companies. Rafael currently serves as director on a number of boards internationally and received his Ph.D. in Materials Science and Mineral Engineering from the University of California, Berkeley.
Microvi is a leading biotechnology company that discovers, develops, manufactures, and commercializes innovative biocatalytic technologies in water, energy and chemical industries. Microvi's pipeline of solutions, created using its proprietary MicroNiche Engineering platform, enable cost-effective economics, are energy efficient and waste free and deliver higher performance than conventional methods. To learn more please visit www.microvi.com.
Karin Kidder, Microvi Biotechnologies, 1-510-344-0668
This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.